It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Zika virus (ZIKV), an arbovirus of global concern, remodels intracellular membranes to form replication sites. How ZIKV dysregulates lipid networks to allow this, and consequences for disease, is poorly understood. Here, we perform comprehensive lipidomics to create a lipid network map during ZIKV infection. We find that ZIKV significantly alters host lipid composition, with the most striking changes seen within subclasses of sphingolipids. Ectopic expression of ZIKV NS4B protein results in similar changes, demonstrating a role for NS4B in modulating sphingolipid pathways. Disruption of sphingolipid biosynthesis in various cell types, including human neural progenitor cells, blocks ZIKV infection. Additionally, the sphingolipid ceramide redistributes to ZIKV replication sites, and increasing ceramide levels by multiple pathways sensitizes cells to ZIKV infection. Thus, we identify a sphingolipid metabolic network with a critical role in ZIKV replication and show that ceramide flux is a key mediator of ZIKV infection.
Zika virus (ZIKV) remodels intracellular membranes for replication, but the role of different lipid types for infection and disease is unclear. Here, the authors perform lipidomics, show perturbation of the lipid network during ZIKV infection and show that ceramides are important for ZIKV infection.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Oregon Health & Science University (OHSU), Department of Molecular Microbiology & Immunology, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)
2 Biological Sciences Division, Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory (PNNL), Richland, USA (GRID:grid.451303.0) (ISNI:0000 0001 2218 3491)
3 Computing and Analytics Division, National Security Directorate, PNNL, Richland, USA (GRID:grid.451303.0) (ISNI:0000 0001 2218 3491)
4 Oregon Health & Science University (OHSU), Department of Molecular Microbiology & Immunology, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Center for Diversity and Inclusion, OHSU, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)
5 University of California San Diego School of Medicine, Departments of Chemistry & Biochemistry and Pharmacology, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
6 University of Saskatchewan, Department of Plant Sciences, College of Agriculture and Bioresources, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X)
7 University of Zurich, University Zurich and University Hospital Zurich, Zurich, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650)
8 Oregon Health & Science University (OHSU), Department of Molecular Microbiology & Immunology, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Division of Infectious Diseases, OHSU, Department of Medicine, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)